2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
3
Breast Neoplasms
3
Sarcoma, Synovial
2
Recurrence
2
Neoplasms
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Lymphoma
2
Liposarcoma, Myxoid
2
Hodgkin Disease
2
Graft vs Host Disease
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Interventions
Valproic Acid
2
Temozolomide
2
Oncolytic Virotherapy
2
Magnetic Resonance Spectroscopy
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
vorasidenib
1
trametinib
1
sonidegib
1
ribociclib
1
pembrolizumab
1
palbociclib
1
mirdametinib
1
interferon gamma-1b
1
imetelstat
1
gallium Ga 68 dotatate
1
fluorodopa F 18
1
fludarabine phosphate
1
fludarabine
1
Verteporfin
1
Thiotepa
1
Tacrolimus
1
Radiotherapy
1
ONC206
1
Mycophenolic Acid
1
Melphalan
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Immunologic Techniques
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Neuroepithelial
×
Interferon-gamma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled